Adam D. Levy - 01 Apr 2025 Form 3 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: Chief Financial Officer
Signature: /s/ Adam D. Levy
Issuer symbol: ACRV
Transactions as of: 01 Apr 2025
Net transactions value: $0
Form type: 3
Filing time: 03 Apr 2025, 16:28:42 UTC
Next filing: 05 Aug 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ACRV	Common Stock						13,315	01 Apr 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ACRV	Stock Option (Right to Buy)							01 Apr 2025	Common Stock	43,425	$11.26	Direct	F2
holding	ACRV	Stock Option (Right to Buy)							01 Apr 2025	Common Stock	38,500	$5.70	Direct	F3
holding	ACRV	Stock Option (Right to Buy)							01 Apr 2025	Common Stock	74,100	$5.31	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares include 10,856 restricted stock units ("RSUs") from an original grant of 14,475 RSUs on August 16, 2023. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of the original 14,475 RSUs granted, twenty-five percent (25%) vested on August 1, 2024, and the remaining RSUs vest in 3 substantially equal annual installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F2	Twenty-five percent (25%) of the shares subject to the option vested on August 1, 2024, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F3	Twenty-five percent (25%) of the shares subject to the option vested on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F4	Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney